Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LP-005 in Moderate-to-Severe Periodontitis
NCT07603713Phase 2Not yet recruiting
- Sponsor
- LongBio Pharma
- Start
- May 2026
- Primary completion
- Nov 2026
- Modality
- Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of LP-005 in periodontitis, sponsored by LongBio Pharma. Planned start May 2026; status: not yet recruiting.
02
Drugs
LP-005
03
Conditions
periodontitis
Beyond the preview
Go deeper on NCT07603713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07603713.